X-linked adrenoleukodystrophy is a rare genetic condition that causes problems with the white matter in your nervous system and adrenal glands. X-linked adrenoleukodystrophy (X-ALD) is a genetic ...

CBS4 - Once a baby is born, all parents care about is the health of their little one. Every year, 4 million babies are tested for diseases, and around 3,000 are positive for something severe. That's ...

(RTTNews) - Viking Therapeutics, Inc. (VKTX), Wednesday announced positive data from Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal ...

Nearly all of the approximately 4 million newborns in the United States undergo screening within the first few days of life, primarily through evaluation of dried blood spots for a wide variety of ...

Viking Therapeutics, Inc. VKTX recently received a setback as the FDA placed a clinical hold on its early-stage study of pipeline candidate VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD ...

SAN DIEGO, June 24, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare genetic neurological diseases, announced the closing of a Series A ...

Viking, which is also developing a weight-loss pill, has a buy rating from all 13 analysts offering coverage Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a ...

Viking Therapeutics Inc.’s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare genetic neurological diseases, announced the closing of a Series A ...